These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16565737)

  • 21. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast.
    Schwartzberg L; Weaver C; Lewkow L; McAneny B; Zhen B; Birch R; West W; Tauer K; Buckner C
    Bone Marrow Transplant; 1999 Nov; 24(9):981-7. PubMed ID: 10556957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M; Al-Kgodary T
    Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.
    Montemurro F; Rondón G; Ueno NT; Munsell M; Gajewski JL; Champlin RE
    Bone Marrow Transplant; 2002 May; 29(10):861-6. PubMed ID: 12058236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.
    Gutierrez-Delgado F; Holmberg LA; Hooper H; Appelbaum FR; Livingston RB; Maziarz RT; Weiden P; Rivkin S; Montgomery P; Kawahara K; Bensinger W
    Bone Marrow Transplant; 2000 Jul; 26(1):51-9. PubMed ID: 10918405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
    Biron P; Durand M; Roché H; Delozier T; Battista C; Fargeot P; Spaeth D; Bachelot T; Poiget E; Monnot F; Tanguy ML; Curé H
    Bone Marrow Transplant; 2008 Mar; 41(6):555-62. PubMed ID: 18037940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
    Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
    Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A
    Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
    Nieto Y; Cagnoni PJ; Shpall EJ; Xu X; Murphy J; Vredenburgh J; Chao NJ; Bearman SI; Jones RB
    Clin Cancer Res; 1999 Nov; 5(11):3425-31. PubMed ID: 10589754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
    Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
    Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.
    Kasper B; Lehnert T; Bernd L; Mechtersheimer G; Goldschmidt H; Ho AD; Egerer G
    Bone Marrow Transplant; 2004 Jul; 34(1):37-41. PubMed ID: 15170176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
    Buijs C; Rodenhuis S; Seynaeve CM; van Hoesel QG; van der Wall E; Smit WJ; Nooij MA; Voest E; Hupperets P; TenVergert EM; van Tinteren H; Willemse PH; Mourits MJ; Aaronson NK; Post WJ; de Vries EG
    J Clin Oncol; 2007 Dec; 25(34):5403-9. PubMed ID: 18048822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
    Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
    J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
    Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
    Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer.
    Vahdat LT; Cohen DJ; Zipin D; Lo KS; Donovan D; Savage D; Tiersten A; Nichols G; Troxel A; Hesdorffer CS
    Bone Marrow Transplant; 2007 Aug; 40(3):267-72. PubMed ID: 17563739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
    Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
    Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.